As part of the implementation of the President of the Republic of Kazakhstan’s directive to increase the share of domestic pharmaceutical production to 50%, a major strategic investment project will be launched in the country.
The corresponding resolution was signed by Prime Minister Olzhas Bektenov. The document approves a draft Investment Agreement between the Ministry of Health of Kazakhstan and LLP “Khan Tengri Biopharma” for the construction of a modern biopharmaceutical complex in the Alatau Special Economic Zone.
The facility will be equipped with advanced technologies for the production of medicines. The key objective is to establish manufacturing capacity for 58 medicinal products.
Special emphasis is placed on establishing a full production cycle, including the manufacturing of active pharmaceutical ingredients (APIs).
The production portfolio will include 27 International Nonproprietary Names (INNs), covering medicines for the treatment of:
Total investment will exceed KZT 103 billion, with more than 180 new permanent jobs to be created.
The project is of strategic importance for the development of Kazakhstan’s pharmaceutical industry and aims to:
Part of the output is planned for export to the markets of the EAEU, CIS countries, and the Middle East.
The corresponding resolution was signed by Prime Minister Olzhas Bektenov. The document approves a draft Investment Agreement between the Ministry of Health of Kazakhstan and LLP “Khan Tengri Biopharma” for the construction of a modern biopharmaceutical complex in the Alatau Special Economic Zone.
The facility will be equipped with advanced technologies for the production of medicines. The key objective is to establish manufacturing capacity for 58 medicinal products.
Special emphasis is placed on establishing a full production cycle, including the manufacturing of active pharmaceutical ingredients (APIs).
The production portfolio will include 27 International Nonproprietary Names (INNs), covering medicines for the treatment of:
- oncology diseases,
- autoimmune disorders,
- rare (orphan) diseases,
- inflammatory conditions.
Total investment will exceed KZT 103 billion, with more than 180 new permanent jobs to be created.
The project is of strategic importance for the development of Kazakhstan’s pharmaceutical industry and aims to:
- expand local production,
- build a sustainable manufacturing base,
- gradually substitute imports of socially significant medicines.
Part of the output is planned for export to the markets of the EAEU, CIS countries, and the Middle East.